These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 39181562

  • 1. Study protocol for the ROLEX-DUO randomised placebo-controlled trial: ROmosozumab Loaded with EXercise - DUal effects on bone and muscle in postmenopausal Osteoporosis and Osteopenia.
    Kumar S, Beck BR, Nery L, Byth K, Elhindi J, Wood C, Fuller OK, Clifton-Bligh RJ, Girgis CM.
    BMJ Open; 2024 Aug 24; 14(8):e086708. PubMed ID: 39181562
    [Abstract] [Full Text] [Related]

  • 2. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A.
    Bone; 2017 Oct 24; 103():209-215. PubMed ID: 28687496
    [Abstract] [Full Text] [Related]

  • 3. The influence of antiresorptive bone medication on the effect of high-intensity resistance and impact training on osteoporotic fracture risk in postmenopausal women with low bone mass: protocol for the MEDEX-OP randomised controlled trial.
    Fischbacher M, Weeks BK, Beck BR.
    BMJ Open; 2019 Sep 05; 9(9):e029895. PubMed ID: 31492784
    [Abstract] [Full Text] [Related]

  • 4. The effect of low-intensity whole-body vibration with or without high-intensity resistance and impact training on risk factors for proximal femur fragility fracture in postmenopausal women with low bone mass: study protocol for the VIBMOR randomized controlled trial.
    Beck B, Rubin C, Harding A, Paul S, Forwood M.
    Trials; 2022 Jan 06; 23(1):15. PubMed ID: 34991684
    [Abstract] [Full Text] [Related]

  • 5. Effects of supervised high-intensity resistance and impact training or machine-based isometric training on regional bone geometry and strength in middle-aged and older men with low bone mass: The LIFTMOR-M semi-randomised controlled trial.
    Harding AT, Weeks BK, Lambert C, Watson SL, Weis LJ, Beck BR.
    Bone; 2020 Jul 06; 136():115362. PubMed ID: 32289518
    [Abstract] [Full Text] [Related]

  • 6. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 06; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 7. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV, Pérez-López FR, Piscoya A, Pasupuleti V, Roman YM, Thota P, Herrera A.
    Maturitas; 2019 Nov 06; 129():12-22. PubMed ID: 31547908
    [Abstract] [Full Text] [Related]

  • 8. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ, Farrerons-Minguella J, Halse J, Kröger H, Maroni M, Mulder H, Muñoz-Torres M, Sääf M, Snorre Øfjord E.
    Clin Ther; 2007 Sep 06; 29(9):1937-49. PubMed ID: 18035193
    [Abstract] [Full Text] [Related]

  • 9. Moxibustion as adjuvant therapy for preventing bone loss in postmenopausal women: protocol for a randomised controlled trial.
    Lu L, Wen Q, Zhang X, Lv J, Zhang L, Liu L, Yu X, Li N.
    BMJ Open; 2022 Dec 12; 12(12):e062677. PubMed ID: 36523246
    [Abstract] [Full Text] [Related]

  • 10. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
    Miyauchi A, Dinavahi RV, Crittenden DB, Yang W, Maddox JC, Hamaya E, Nakamura Y, Libanati C, Grauer A, Shimauchi J.
    Arch Osteoporos; 2019 Jun 05; 14(1):59. PubMed ID: 31168657
    [Abstract] [Full Text] [Related]

  • 11. The LIFTMOR-M (Lifting Intervention For Training Muscle and Osteoporosis Rehabilitation for Men) trial: protocol for a semirandomised controlled trial of supervised targeted exercise to reduce risk of osteoporotic fracture in older men with low bone mass.
    Harding AT, Weeks BK, Watson SL, Beck BR.
    BMJ Open; 2017 Jun 12; 7(6):e014951. PubMed ID: 28611110
    [Abstract] [Full Text] [Related]

  • 12. High-Intensity Resistance and Impact Training Improves Bone Mineral Density and Physical Function in Postmenopausal Women With Osteopenia and Osteoporosis: The LIFTMOR Randomized Controlled Trial.
    Watson SL, Weeks BK, Weis LJ, Harding AT, Horan SA, Beck BR.
    J Bone Miner Res; 2018 Feb 12; 33(2):211-220. PubMed ID: 28975661
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL, Bone HG, Massari F, Gielen E, Palacios S, Maddox J, Yan C, Yue S, Dinavahi RV, Libanati C, Grauer A.
    Osteoporos Int; 2019 Dec 12; 30(12):2437-2448. PubMed ID: 31628490
    [Abstract] [Full Text] [Related]

  • 15. A Comparison of Bone-Targeted Exercise With and Without Antiresorptive Bone Medication to Reduce Indices of Fracture Risk in Postmenopausal Women With Low Bone Mass: The MEDEX-OP Randomized Controlled Trial.
    Kistler-Fischbacher M, Yong JS, Weeks BK, Beck BR.
    J Bone Miner Res; 2021 Sep 12; 36(9):1680-1693. PubMed ID: 34033146
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia).
    Fujiwara S, Hamaya E, Sato M, Graham-Clarke P, Flynn JA, Burge R.
    Clin Interv Aging; 2014 Sep 12; 9():1879-93. PubMed ID: 25395843
    [Abstract] [Full Text] [Related]

  • 18. Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.
    Medical Advisory Secretariat.
    Ont Health Technol Assess Ser; 2006 Sep 12; 6(20):1-180. PubMed ID: 23074491
    [Abstract] [Full Text] [Related]

  • 19. Romosozumab in postmenopausal women with low bone mineral density.
    McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG.
    N Engl J Med; 2014 Jan 30; 370(5):412-20. PubMed ID: 24382002
    [Abstract] [Full Text] [Related]

  • 20. The effect of Cissus quadrangularis L. on delaying bone loss in postmenopausal women with osteopenia: A randomized placebo-controlled trial.
    Benjawan S, Nimitphong H, Tragulpiankit P, Musigavong O, Prathanturarug S, Pathomwichaiwat T.
    Phytomedicine; 2022 Jul 30; 101():154115. PubMed ID: 35523116
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.